

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2001. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/792,191
		Filing Date	March 3, 2004
		First Named Inventor	Chun-Ying Huang
		Group Art Unit	1818 / 618
		Examiner Name	Not Yet Assigned DJones
Sheet	2		2
		Attorney Docket Number	0624-040488


<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.	T <sup>2</sup>
	1	Zhi-Xiang Shen et al, Use of Arsenic Trioxide (As <sub>2</sub> O <sub>3</sub> ) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients, BLOOD, Vol 89, No. 9, May 1, 1997: pp. 3354-3360	
	2	Zhen-Yi Wang, Arsenic Compounds as Anticancer Agents, CANCER CHEMOTHERAPY AND PHARMACOLOGY, DOI 10.1007/s002800100309, Published Online: 27 November 2001	
	3	Shen Y et al., Studies on the Clinical Efficacy and Pharmacokinetics of Low-Dose Arsenic Trioxide in the Treatment of Relapsed Acute Promyelocytic Leukemia: A Comparison With Conventional Dosage, LEUKEMIA 2001, May: 15(5): pages 735-41	
	4	Muto A. et al, A Novel Differentiation-Inducing Therapy for Acute Promyelocytic Leukemia With a Combination of Arsenic Trioxide and GM-CSF, LEUKEMIA 2001, Aug: 15(8): pages 1176-84	
	5	Guo-Qiang Chen et al., Use of Arsenic Trioxide (As <sub>2</sub> O <sub>3</sub> ) in the Treatment of Acute Promyelocytic Leukemia (APL): I. As <sub>2</sub> O <sub>3</sub> Exerts Dose-Dependent Dual Effects on APL Cells, BLOOD, Vol 89, No. 9, May 1, 1997, pages 3345-3353	
	6	Wilson H. Miller et al., Mechanisms of Action of Arsenic Trioxide, CANCER RESEARCH 62, July 15, 2002, pages 3893-3903	
	7	Anthony J. Murgo, Clinical Trials of Arsenic Trioxide in Hematologic and Solid Tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies, THE ONCOLOGIST 2001; 6 (Suppl. 2), pages 22-28	
	8	Study on Anti-Tumor Activity of Arsenic Trioxide, CHINA JOURNAL OF CHINESE MATERIA MEDICA (1999), 24(3), pages 1-3	
	9	Meral Tayan Ercan et al., Therapeutic Radiopharmaceuticals, CURRENT PHARMACEUTICAL DESIGN, 2000, 6., pages 1085-1121	
	10	Yong-Jin Chun et al., Enhancement of Radiation Response in Human Cervical Cancer Cells In Vitro and in Vivo by Arsenic Trioxide (As <sub>2</sub> O <sub>3</sub> ), FEBS LETTERS 519, (2002), pages 195-200	
	11	Samir C. Mehta et al., Targeted Drug Delivery for Boron Neutron Capture Therapy, PHARMACEUTICAL RESEARCH, Vol. 13, No. 3, 1996, pages 344-351	

Examiner Signature		Date Considered	4/23/07
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08a (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/792,191
Filing Date	March 3, 2004
First Named Inventor	Chun-Ying Huang
Art Unit	1616-1608
Examiner Name	Not Yet Assigned P. Jones
Attorney Docket Number	0624-040488

Sheet	1	of	1
-------	---	----	---

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
A	1	MEHTA et al., "Targeted Drug Delivery for Boron Neutron Capture Therapy", Pharmaceutical Research, 1996, Vol. 13, No. 3, Plenum Publishing Corporation.
D		Brunet C et al., "Whole Body Auto Radiographic Study of the Distribution of Radioactivity in Pregnant Mice Given Arsenic-73 Labelled Arsenic Tri Oxide", Toxicological European Research, vol. 5, no. 2, 1983, pages 55-62.
D		Chun Yong Jin et al., "Enhancement of Radiation Response in Human Cervical Cancer Cells in Vitro and in Vivo by Arsenic Trioxide (As2O3)". Febs Letters, 22 May 2002, vol. 519, no. 1-3, pages 195-200.


Examiner Signature		Date Considered	4/22/07
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

(W0232223.1)



PTO/SB/08b (07/05)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/792,191
				Filing Date	March 3, 2004
				First Named Inventor	Chun-Ying HUANG
				Art Unit	4616 PL618
				Examiner Name	Not Yet Assigned Done
Sheet	1	of	1	Attorney Docket Number	0624-040488

[illegible]

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

{W0327584.1}